Real-World Patient Characteristics, Treatment Patterns, and Outcomes for Patients with HER2 Negative Metastatic Breast Cancer Treated with Sacituzumab Govitecan: a Retrospective Trial in ChinaSACIT-OUT
Latest Information Update: 24 Jan 2025
Price :
$35 *
At a glance
- Drugs Sacituzumab govitecan (Primary)
- Indications Breast cancer; HER2 negative breast cancer
- Focus Therapeutic Use
- Acronyms SACIT-OUT
- 24 Jan 2025 New trial record